TIDMNSCI
RNS Number : 5206P
NetScientific PLC
18 November 2016
("NetScientific" or the "Company" or the "Group")
Portfolio Company Vortex Bioscience's circulating tumour cell
(CTC) technology used in analysis demonstrating the value of
combining CTCs and circulating free DNA (cfDNA)
Demonstrates the Value of Combining CTCs and cfDNA in Assessing
Cancer Patient Disease
London, UK - November 18 - NetScientific plc (AIM:NSCI), the
transatlantic healthcare IP commercialisation group, announces that
technology from its portfolio company, Vortex Biosciences, was used
in an analysis, published in peer-reviewed Oncotarget, of the
merits of various approaches to assessing the mutation profiles in
tumours.
The analysis compared circulating tumour cells (CTCs),
circulating free DNA (cfDNA) and tumour biopsy data, and found that
all approaches had advantages and limitations, but that the
analysis of CTC and cfDNA together appears to enhance the ability
to assess the mutation profile and metastatic status of a
tumour.
Commenting on the news, NetScientific's Chief Executive Officer
and Chairman of Vortex, Francois R. Martelet, said: "These findings
are not only very significant for Vortex but critical to the
ongoing debate about the merits of these technologies. They appear
to support the use of a complementary approach, using both
technologies, to diagnose and monitor tumours and their mutation
profile.
"We are very pleased that Vortex's technology has played such a
critical part in this important study."
Vortex Bioscience's press release follows:
Vortex Biosciences Announces Publication in Oncotarget That
Demonstrates the Value of Combining CTCs and cfDNA in Assessing
Cancer Patient Disease
Mutation Profiles from Matched Tumor and Blood Samples were
Compared between the Tumor, cfDNA and CTCs
MENLO PARK, CA, November 17, 2016 - Vortex Biosciences, provider
of circulating tumor cell (CTC) capture systems, today announced
the publication of "Enumeration and targeted analysis of KRAS, BRAF
and PIK3CA mutations in CTCs captured by a label-free platform:
Comparison to ctDNA and tissue in metastatic colorectal cancer" in
Oncotarget on November 15th, 2016.
The peer reviewed publication describes the use of Vortex
technology to capture CTCs and compare mutation profiles in the CTC
DNA, cfDNA, and tumor biopsy DNA. There were several examples where
CTCs exhibited a mutation that was not detected in ctDNA, and vice
versa. Complementary assessment of both CTCs and ctDNA appears
advantageous to assess dynamic tumor profiles.
From 15 patients with advanced CRC undergoing liver
metastasectomy with curative intent, 41 blood samples were
collected at different time points before and after liver surgery
for CTC-isolation and quantification using the Vortex
technology.
The Vortex Bioscience technology captures unlabelled CTCs in
whole blood by trapping the cells in microscale vortices while
smaller red and white blood cells pass through. After selective
trapping of the CTCs in microfluidic chambers, CTCs are flushed and
collected into a variety of containers for downstream analysis. In
this publication, KRAS, BRAF, and PIK3CA hotspot mutations were
analyzed in CTCs and cfDNA from 23 samples, 9 matched liver
metastases and 3 primary tumor samples.
"We see CTCs and cfDNA as complementary to each other, together
offering a better understanding of a patient's disease," said Gene
Walther, Chief Executive Officer of Vortex Biosciences. "Our next
generation CTC capture system allows for the collection of CTCs
after the plasma has been removed for cfDNA extraction in a simple,
easy to use workflow."
80% of patient blood samples were positive for CTCs, using a
healthy baseline value as a threshold. This includes 19% of
patients that were EpCAM negative and thus would not have been
identified by CTC enrichment technologies targeting EpCAM. Among 23
matched CTC and cfDNA samples, we found a concordance of 78.2% for
KRAS, 73.9% for BRAF and 91.3% for PIK3CA mutations. The
concordance with the tumor samples for CTCs and ctDNA respectively
was 72% and 76%. However, when the mutation profile detected in
CTCs and cfDNA was combined, the concordance with the tumor was
>95%.
With the ability to capture both CTCs and cfDNA in a simple
workflow, the Vortex technology can seamlessly integrate into a
genomic testing process, transforming the way patient samples can
be analyzed.
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Ian Postlethwaite, CFO
Stifel Nicolaus Europe Limited Tel: +44 (0) 20 7710
(NOMAD and broker) 7600
Jonathan Senior / David
Arch / Ben Maddison
Consilium Strategic Communications Tel: +44 (0)20 3709
Mary-Jane Elliott / Jessica 5700
Hodgson / Chris Welsh / netscientific@consilium-comms.com
Laura Thornton
About NetScientific Plc
NetScientific is a transatlantic healthcare IP commercialisation
group focused on improving the health and well-being of people with
chronic diseases. For more information, please visit the website at
www.netscientific.net.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex technology will enable the
harvesting of intact circulating tumor cells from whole blood
samples for use in downstream research and clinical applications
such as patient stratification in clinical trials, monitoring
disease progression and drug treatment effectiveness. [include that
the first test is CE Marked?]With a mission to enable noninvasive
diagnosis of cancer and real-time monitoring throughout a patient's
treatment, Vortex is at the forefront of accelerating cancer
research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLFFIVLDLDLIR
(END) Dow Jones Newswires
November 18, 2016 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024